288. 自己免疫性後天性凝固因子欠乏症 [臨床試験数:189,薬物数:219(DrugBank:29),標的遺伝子数:18,標的パスウェイ数:26

Searched query = "Autoimmune acquired coagulation factor deficiency", "Coagulation factor deficiency", "Factor XIII deficiency", "Factor VIII deficiency", "Acquired hemophilia A", "von Willebrand Disease", "Factor V deficiency"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03700229October 10, 20184/10/2018Study to Evaluate Rituximab and Bortezomib in Patients With Newly Diagnosed Acquired Hemophilia AAn Open-label Phase II Study to Determine the Efficacy and Safety of Rituximab and Bortezomib in Patients With Newly Diagnosed Acquired Hemophilia AAcquired Hemophilia ADrug: Bortezomib;Drug: RituximabPeking Union Medical College HospitalNULLUnknown status18 YearsN/AAll22Phase 2China
2NCT03384277October 26, 201728/11/2017Trial of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With RituximabA Prospective, Randomized, Multicenter Clinical Trial of Acquired Haemophilia A With Steroid Combined With Cyclophosphamide Versus Steroid Combined With RituximabAcquired Hemophilia ADrug: Steroid;Drug: Rituximab;Drug: CyclophosphamideZhang LeiQilu Hospital of Shandong University;Tianjin First Central Hospital;The Second Affiliated Hospital of Kunming Medical University;Henan Cancer HospitalRecruiting18 Years80 YearsAll100Phase 3China
3NCT00306670April 200623/3/2006Trial of Rituximab Versus Oral Cyclophosphamide to Eradicate or Suppress Autoimmune Anti-Factor VIII Antibodies in Acquired Hemophilia AA Prospective, Phase II/III Randomized, Mult-institutional Controlled, Open-label, Phase II Trial of Rituximab Versus Oral Cyclophosphamide to Eradicate or Suppress Autoimmune Anti-Factor VIII Antibodies in Patients With Acquired Hemophilia AHemophilia ADrug: Rituxan;Drug: prednisoneGeorgetown UniversityGenentech, Inc.Terminated18 Years65 YearsAll2Phase 2/Phase 3United States